Department of Pathobiology, College of Veterinary Medicine, 127 Sugg Laboratory, Auburn University, AL 36849-5516, USA.
Antiviral Res. 2013 Oct;100(1):133-50. doi: 10.1016/j.antiviral.2013.07.015. Epub 2013 Aug 6.
The pestiviruses, bovine viral diarrhea virus (BVDV), classical swine fever (CSFV) and border disease virus, are important livestock pathogens in many countries, but current vaccines do not completely prevent the spread of infection. Control of pestiviral diseases is especially difficult due to the constant viremia and viral shedding of persistently infected (PI) animals, which must be identified and eliminated to prevent disease transmission. Existing vaccines are limited by the delay between vaccination and the onset of protection, the difficulty of differentiating serologically between vaccinated and naturally infected animals and the need for broad vaccine cross-protection against diverse virus strains. Antiviral therapy could potentially supplement vaccination by providing immediate protection in the case of an outbreak. Numerous compounds with in vitro antiviral activity against BVDV have been identified through its role as a surrogate for hepatitis C virus. Fewer drugs active against CSFV have been identified, but many compounds that are effective against BVDV will likely inhibit CSFV, given their similar genomic sequences. While in vitro research has been promising, the paucity of efficacy studies in animals has hindered the commercial development of effective antiviral drugs against the pestiviruses. In this article, we summarize the clinical syndromes and routes of transmission of BVD, CSF and border disease, discuss currently approved vaccines, review efforts to develop antiviral therapies for use in outbreak control and suggest promising directions for future research.
该瘟病毒,牛病毒性腹泻病毒(BVDV),古典猪瘟(CSFV)和边界病病毒,是在许多国家的重要牲畜病原体,但目前的疫苗不能完全阻止感染的传播。瘟病毒病的控制是特别困难的,由于持续感染(PI)动物的恒定病毒血症和病毒脱落,必须识别和消除,以防止疾病传播。现有的疫苗受到限制之间的延迟接种和保护作用的开始,在血清学上区分接种和自然感染的动物的困难和需要广泛的疫苗交叉保护对不同的病毒株。抗病毒治疗可以通过在爆发的情况下提供即时保护来补充疫苗接种。通过其作为丙型肝炎病毒的替代物,已经鉴定出许多对 BVDV 具有体外抗病毒活性的化合物。已经鉴定出对 CSFV 有活性的药物较少,但对 BVDV 有效的许多化合物很可能会抑制 CSFV,因为它们具有相似的基因组序列。虽然体外研究很有希望,但在动物中缺乏疗效研究阻碍了针对瘟病毒的有效抗病毒药物的商业开发。在本文中,我们总结了 BVD、CSF 和边界病的临床综合征和传播途径,讨论了目前批准的疫苗,综述了开发用于控制爆发的抗病毒疗法的努力,并提出了未来研究的有希望的方向。